Rocket Pharmaceu Stock Price, News & Analysis

Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q3 2021 financial results with a net loss of $50.1 million or $0.79 per share, up from $29.1 million or $0.53 per share in Q3 2020. The company holds $421.5 million in cash, expected to fund operations into 2H 2023. Treatment in the Danon Disease trial commenced for pediatric patients, while the LAD-I trial reported positive interim results with favorable safety and efficacy in all seven patients. Comprehensive clinical updates are anticipated at upcoming AHA and ASH meetings.

Frazier Healthcare Partners announced the closing of Frazier Life Sciences Public Fund, raising nearly $830 million in an oversubscribed fund. This marks Frazier's first dedicated public life sciences fund, increasing total capital raised to over $7.1 billion. The fund targets investments in small- and mid-cap public biotech firms. Recent successful exits include Rocket Pharmaceuticals (NASDAQ: RCKT), Translate Bio (NASDAQ: TBIO), and Trillium Therapeutics (pending acquisition by Pfizer).

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announces CEO Gaurav Shah will present at the 2021 Cell & Gene Meeting on the Mesa in Carlsbad, CA, on Tuesday, October 12, at 2:15 p.m. PST. The presentation will be available via a live audio webcast for registered attendees, with a recorded version accessible within 24 hours. Rocket focuses on genetic therapies for rare childhood disorders, with programs targeting conditions such as Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Infantile Malignant Osteopetrosis, utilizing both lentiviral vector and adeno-associated virus technologies.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced participation in the Chardan Virtual 5th Annual Genetic Medicines Conference. CEO Gaurav Shah will join a fireside chat on October 5, 2021, at 10:30 am ET, while CMO Jonathan Schwartz will discuss genetic medicines on a panel on October 4, 2021, at 3:00 pm ET. The event's webcast will be available on Rocket's website, with an archive accessible for 30 days.

Rocket focuses on genetic therapies for rare childhood disorders, including Fanconi Anemia and Danon disease.

Rocket Pharmaceuticals (NASDAQ: RCKT) presented positive data from its ongoing Phase 1 trial of RP-A501 for Danon Disease at the HFSA Annual Scientific Meeting 2021. The low-dose cohort (6.7e13 vg/kg) demonstrated that RP-A501 was well tolerated, with all patients showing clinical improvement, sustained cardiac expression, and a manageable safety profile. Rocket plans to initiate treatment in a pediatric cohort in Q3 and expects comprehensive updates in Q4.

Rocket Pharmaceuticals (NASDAQ: RCKT) announced that data from the ongoing Phase 1 trial of RP-A501, a gene therapy for Danon Disease, will be presented in a late-breaking session at the Heart Failure Society of America Annual Scientific Meeting 2021, held from September 10-13, 2021, in Aurora, Colorado. The presentation is scheduled for September 13, 2021, highlighting that preliminary data from the low-dose cohort showed general tolerability and improved cardiac function.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has appointed Isabel Carmona as Chief Human Resources Officer and Senior Vice President. With over 25 years of experience, particularly in life sciences, Carmona will oversee all HR functions and contribute to Rocket's growth strategy. CEO Gaurav Shah emphasized her expertise in talent management as crucial for the company's expansion. Carmona previously served as CHRO at Ichnos Sciences, enhancing her capabilities in developing organizational frameworks. The leadership team, noted for extensive drug development experience, aims to advance Rocket's innovative gene therapies for rare diseases.